Literature DB >> 36116091

The Skin and Gut Microbiome in Hidradenitis Suppurativa: Current Understanding and Future Considerations for Research and Treatment.

Marisa E Luck1, Joy Tao2, Eden P Lake2.   

Abstract

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease comprising painful abscesses, deep nodules, fistulas, and scarring predominantly in the axilla and groin. Bacterial colonization of HS lesions has been well characterized and may lead to chronic infection of lesions. While disease pathogenesis of HS is not fully understood, there is increasing evidence that microbial dysbiosis may be occurring in numerous locations, including the skin and gut. The skin-gut microbiome has been proposed as a mechanism by which inflammatory skin disorders, including HS, can be exacerbated. This is evidenced by HS patients being significantly more likely to develop inflammatory bowel disease as well as the well documented cutaneous manifestations in inflammatory bowel disease. In this review, we discuss the current literature regarding HS skin and gut microbiome research. Furthermore, we discuss further considerations for microbiome research in HS, including the potential role of bacterial metabolites in disease progression and future therapeutic avenues like probiotics.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Year:  2022        PMID: 36116091     DOI: 10.1007/s40257-022-00724-w

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   6.233


  117 in total

Review 1.  A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris.

Authors:  James Q Del Rosso; Nicholas F Schmidt
Journal:  Cutis       Date:  2010-01

Review 2.  Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis.

Authors:  Samantha R Goldburg; Bruce E Strober; Michael J Payette
Journal:  J Am Acad Dermatol       Date:  2019-10-09       Impact factor: 11.527

3.  The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction.

Authors:  Ellen Witte-Händel; Kerstin Wolk; Athanasia Tsaousi; Marie Luise Irmer; Rotraut Mößner; Orr Shomroni; Thomas Lingner; Katrin Witte; Desiree Kunkel; Gabriela Salinas; Stefan Jodl; Nicole Schmidt; Wolfram Sterry; Hans-Dieter Volk; Evangelos J Giamarellos-Bourboulis; Anna Pokrywka; Wolf-Dietrich Döcke; Sylke Schneider-Burrus; Robert Sabat
Journal:  J Invest Dermatol       Date:  2018-12-05       Impact factor: 8.551

4.  Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Authors:  Alexa B Kimball; Francisco Kerdel; David Adams; Ulrich Mrowietz; Joel M Gelfand; Robert Gniadecki; Errol P Prens; Joel Schlessinger; Christos C Zouboulis; Hessel H van der Zee; Marie Rosenfeld; Parvez Mulani; Yihua Gu; Susan Paulson; Martin Okun; Gregor B E Jemec
Journal:  Ann Intern Med       Date:  2012-12-18       Impact factor: 25.391

5.  Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.

Authors:  Vassiliki Tzanetakou; Theodora Kanni; Sophia Giatrakou; Alexandros Katoulis; Evangelia Papadavid; Mihai G Netea; Charles A Dinarello; Jos W M van der Meer; Dimitrios Rigopoulos; Evangelos J Giamarellos-Bourboulis
Journal:  JAMA Dermatol       Date:  2016-01       Impact factor: 10.282

6.  Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum.

Authors:  J L Blok; K Li; C Brodmerkel; P Horvátovich; M F Jonkman; B Horváth
Journal:  Br J Dermatol       Date:  2016-01-27       Impact factor: 9.302

Review 7.  Hidradenitis Suppurativa: Advances in Diagnosis and Treatment.

Authors:  Ditte Marie Lindhardt Saunte; Gregor Borut Ernst Jemec
Journal:  JAMA       Date:  2017-11-28       Impact factor: 56.272

Review 8.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

9.  Mechanism of anti-inflammatory effects of rifampicin in an ex vivo culture system of hidradenitis suppurativa.

Authors:  Isabel Haferland; Chantal M Wallenwein; Tanja Ickelsheimer; Sandra Diehl; Matthias G Wacker; Susanne Schiffmann; Claudia Buerger; Roland Kaufmann; Anke Koenig; Andreas Pinter
Journal:  Exp Dermatol       Date:  2022-01-28       Impact factor: 4.511

10.  A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP).

Authors:  E Delany; G Gormley; R Hughes; S McCarthy; S Kirthi; T Markham; A-M Tobin; M Murphy; B Kirby
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-12-06       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.